Regulatory News

NOTICE OF FINANCIAL RESULTS 1H2012 IFRS ANNOUNCEMENT DATE

Moscow, 10 August 2012 -Pharmstandard OJSC (LSE: PHST IL, MICEX-RTS: PHST RU),
will be announcing its financial results for 1H2012 (unaudited) on Wednesday, August  29, 2012.

Pharmstandard is pleased to invite the investment and mass media community to conference call with the management of the company followed by a Q&A session.

Wednesday, August 29, 2012

09:00 New York

14:00 London

17:00 Moscow

International Call-in Number:  +44 207 162 0025

US Call-in Number: +1 334 323 6201
Conference ID: 921237

Conference call participants can register in advance using the link below:

https://eventreg1.conferencing.com/webportal3/reg.html?Acc=097741&Conf=184827

We recommend that participants start dialling in 5-10 minutes prior to ensure a timely start to the conference call.

Pharmstandard will be represented by:

Igor Krylov, CEO

Elena Arkhangelskaya, CFO

Ilya Krylov, IR officer

Press release & presentation will be available on Wednesday, August 29, 2012 on Company's web-site:
www.pharmstd.com  

The conference call replay will be available through 7, September 2012

International Replay Number: +44 207 031 4064

Replay Access Code: 921237

Contacts:

Ilya Krylov
IR officer
Pharmstandard JSC

Tel: +7 495 970 0030 ext 2416

E-mail: ir@pharmstd.ru
www.pharmstd.ru

About the Pharmstandard group of companies

The main sphere of activity of the enterprises comprising the Pharmstandard group of companies, are developing and manufacturing of high-quality modern pharmaceutical products which meet the requirements of the healthcare system and the expectations of patients.

The most well known Pharmstandard products today are Arbidol®, Complivit®, Pentalgin®, Flucostat®, Phosphoglive®, Amixin®, Afobazol®, Rastan® and Biosulin®. The Pharmstandard group of companies manufactures more than 250 pharmaceutical products, including medicines for the treatment of cardio-vascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, contagious diseases, metabolic disorders, cancer and other diseases. More than 100 Pharmstandard products (taking into account all forms and dosages) are included in the list of Vital and Essential Pharmaceuticals.

In the period from 2004 to 2011 more than 60 new pharmaceutical products were developed by Pharmstandard, in co-operation with the leading Russian scientific centres. Pharmstandard is a participant in a joint bio-engineering project, Generium, whose objective is the development of socially significant pharmaceutical products within the framework of the state program of import substitution.

By 2011 the Ñompany's aggregate production capacity has reached more than 1,46 billion packages per year. The production capacity of the Pharmstandard group of companies comprises four modern pharmaceutical plants: JSC Pharmstandard-Leksredstva (Kursk), JSC Pharmstandard-UfaVita (Ufa), JSC Pharmstandard-Tomskhimpharm (Tomsk), JSC Pharmstandard-Biolek (Kharkov, Ukraine) and the medical equipment and tools plant JSC TZMOI (Tyumen); Pharmstandard LLC is responsible for the purchase and supply of raw materials for manufacturing of pharmaceutical products at the production facilities of the Pharmstandard group of companies.

All the production facilities of the Pharmstandard group of companies fully comply with Russian national standards, while six production lines at JSC Pharmstandard-Leksredstva have already received certificates of compliance with the EU GMP standards. All the plants are expected to convert to European GMP standards by 2014, according to the schedule approved by the company's management.

On 4 May 2007 Pharmstandard placed its shares during IPO on Russian Trading System (RTS), Moscow Interbank Currency Exchange (MICEX) and Global Depositary Receipts (GDR) at London Stock Exchange (LSE).

www.pharmstd.com